Skip to main content
Top
Published in: BMC Infectious Diseases 1/2023

Open Access 01-12-2023 | Ivermectin | Research

Non-adherence to ivermectin in onchocerciasis-endemic communities with persistent infection in the Bono Region of Ghana: a mixed-methods study

Authors: Kenneth Bentum Otabil, María-Gloria Basáñez, Blessing Ankrah, Emmanuel John Bart-Plange, Theophilus Nti Babae, Prince-Charles Kudzordzi, Vera Achiaa Darko, Abdul Sakibu Raji, Lydia Datsa, Andrews Agyapong Boakye, Michael Tawiah Yeboah, Joseph Nelson Siewe Fodjo, Henk D. F. H. Schallig, Robert Colebunders

Published in: BMC Infectious Diseases | Issue 1/2023

Login to get access

Abstract

Background

The World Health Organization has proposed that onchocerciasis elimination (interruption) of transmission be verified in 12 (approximately a third) endemic countries by 2030. The strategy to reach this goal is based on ivermectin Mass Drug Administration (MDA) with high geographical and therapeutic coverage. In addition to coverage, high levels of treatment adherence are paramount. We investigated factors associated with ivermectin intake in an area of Ghana with persistent Onchocerca volvulus infection.

Methods

In August 2021, a cross-sectional mixed-methods study was conducted in 13 onchocerciasis-endemic communities in the Bono Region of Ghana. Individuals aged ≥ 10 years were invited to participate in a questionnaire survey. A total of 48 focus group discussions and in-depth interviews with 10 community drug distributors and 13 community leaders were conducted.

Results

A total of 510 people participated in the study [median age: 32, interquartile range 30 (20‒50) years]; 274 (53.7%) were females. Of the total, 320 (62.7%) declared that they adhered to each treatment round and 190 (37.3%) admitted they had not taken ivermectin during at least one MDA round, since becoming eligible for treatment. Of 483 participants with complete information, 139 (28.8%) did not take ivermectin during the last round (March 2021), and 24 (5.0%) had never taken ivermectin (systematic non-adherers). Reasons for not taking ivermectin included previous experience/fear of side-effects, being absent during MDA, pregnancy, the desire to drink alcohol, and drug distribution challenges. Being male, having good knowledge and perception of the disease, and not having secondary or higher level of formal education were significantly associated with higher odds of ivermectin intake.

Conclusions

A relatively high level of non-adherence to ivermectin treatment was documented. There is a need for targeted educational and behavioural change campaigns to reverse these trends and ensure a steady course toward meeting onchocerciasis elimination targets in Ghana.
Appendix
Available only for authorised users
Footnotes
1
Adherence is an active process in which a patient takes responsibility for their overall well-being, while compliance is a passive behaviour in which a patient is following a list of recommendations. Mir TH. Adherence versus compliance. HCA Healthc J Med. 2023;4: 219–220.
 
2
The quasi information criterion (QIC) has been proposed as an alternative to Akaike’s information criterion (AIC) for regression analysis based on GEE (Pan W. Akaike’s Information Criterion in Generalized Estimating Equations. Biometrics.2001;57:120–25).
 
Literature
1.
go back to reference Duke BOL. Human onchocerciasis—an overview of the Disease. Acta Leiden. 1990;59:9–24.PubMed Duke BOL. Human onchocerciasis—an overview of the Disease. Acta Leiden. 1990;59:9–24.PubMed
5.
go back to reference Otabil KB, Ankrah B, Bart-Plange EJ, Donkoh ES, Avarikame FA, Ofori-Appiah FO, et al. Prevalence of epilepsy in the onchocerciasis endemic middle belt of Ghana after 27 years of mass drug administration with ivermectin. Infect Dis Poverty. 2023;12(1):75.CrossRefPubMedPubMedCentral Otabil KB, Ankrah B, Bart-Plange EJ, Donkoh ES, Avarikame FA, Ofori-Appiah FO, et al. Prevalence of epilepsy in the onchocerciasis endemic middle belt of Ghana after 27 years of mass drug administration with ivermectin. Infect Dis Poverty. 2023;12(1):75.CrossRefPubMedPubMedCentral
8.
go back to reference Turner HC, Walker M, Churcher TS, Osei-Atweneboana MY, Biritwum NK, Hopkins A, et al. Reaching the London declaration on neglected tropical diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa. Clin Infect Dis. 2014;59(7):923–32.CrossRefPubMedPubMedCentral Turner HC, Walker M, Churcher TS, Osei-Atweneboana MY, Biritwum NK, Hopkins A, et al. Reaching the London declaration on neglected tropical diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa. Clin Infect Dis. 2014;59(7):923–32.CrossRefPubMedPubMedCentral
10.
go back to reference Elphick-Pooley T, Engels D. Uniting to Combat NTDs. World NTD Day 2022 and a new Kigali Declaration to galvanise commitment to end neglected Tropical Diseases. Infect Dis Poverty. 2022;11:2.CrossRefPubMedPubMedCentral Elphick-Pooley T, Engels D. Uniting to Combat NTDs. World NTD Day 2022 and a new Kigali Declaration to galvanise commitment to end neglected Tropical Diseases. Infect Dis Poverty. 2022;11:2.CrossRefPubMedPubMedCentral
11.
go back to reference Basáñez MG, Pion SDS, Boakes E, Filipe JAN, Churcher TS, Boussinesq M. Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8:310–22.CrossRefPubMed Basáñez MG, Pion SDS, Boakes E, Filipe JAN, Churcher TS, Boussinesq M. Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8:310–22.CrossRefPubMed
12.
go back to reference Plaisier AP, Alley ES, Boatin BA, Van Oortmarssen GJ, Remme H, De Vlas SJ, et al. Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the Onchocerciasis Control Programme in West Africa. J Infect Dis. 1995;172:204–10.CrossRefPubMed Plaisier AP, Alley ES, Boatin BA, Van Oortmarssen GJ, Remme H, De Vlas SJ, et al. Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the Onchocerciasis Control Programme in West Africa. J Infect Dis. 1995;172:204–10.CrossRefPubMed
13.
go back to reference Walker M, Pion SDS, Fang H, Gardon J, Kamgno J, Basáñez MG, et al. Macrofilaricidal efficacy of repeated doses of ivermectin for the treatment of river blindness. Clin Infect Dis. 2017;65:2026–34.CrossRefPubMedPubMedCentral Walker M, Pion SDS, Fang H, Gardon J, Kamgno J, Basáñez MG, et al. Macrofilaricidal efficacy of repeated doses of ivermectin for the treatment of river blindness. Clin Infect Dis. 2017;65:2026–34.CrossRefPubMedPubMedCentral
14.
go back to reference Kura K, Milton P, Hamley JID, Walker M, Bakajika DK, Kanza EM, et al. Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa? Philos Trans R Soc Lond B Biol Sci. 2023;378:20220277.CrossRefPubMedPubMedCentral Kura K, Milton P, Hamley JID, Walker M, Bakajika DK, Kanza EM, et al. Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa? Philos Trans R Soc Lond B Biol Sci. 2023;378:20220277.CrossRefPubMedPubMedCentral
15.
go back to reference Traore MO, Sarr MD, Badji A, Bissan Y, Diawara L, Doumbia K, et al. Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. PLoS Negl Trop Dis. 2012;6:e1825.CrossRefPubMedPubMedCentral Traore MO, Sarr MD, Badji A, Bissan Y, Diawara L, Doumbia K, et al. Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. PLoS Negl Trop Dis. 2012;6:e1825.CrossRefPubMedPubMedCentral
16.
go back to reference Tekle AH, Elhassan E, Isiyaku S, Amazigo UV, Bush S, Noma M, et al. Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control. Parasit Vectors. 2012;5:28.CrossRefPubMedPubMedCentral Tekle AH, Elhassan E, Isiyaku S, Amazigo UV, Bush S, Noma M, et al. Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control. Parasit Vectors. 2012;5:28.CrossRefPubMedPubMedCentral
17.
go back to reference Zarroug IM, Hashim K, ElMubark WA, Shumo ZA, Salih KA, ElNojomi NA, et al. The first confirmed elimination of an onchocerciasis focus in Africa: Abu Hamed, Sudan. Am J Trop Med Hyg. 2016;95:1037–40.CrossRefPubMedPubMedCentral Zarroug IM, Hashim K, ElMubark WA, Shumo ZA, Salih KA, ElNojomi NA, et al. The first confirmed elimination of an onchocerciasis focus in Africa: Abu Hamed, Sudan. Am J Trop Med Hyg. 2016;95:1037–40.CrossRefPubMedPubMedCentral
18.
go back to reference Katabarwa MN, Lakwo T, Habomugisha P, Unnasch TR, Garms R, Hudson-Davis L, et al. After 70 years of fighting an age-old scourge, onchocerciasis in Uganda, the end is in sight. Int Health. 2018;10(Suppl 1):i79–i88.CrossRefPubMed Katabarwa MN, Lakwo T, Habomugisha P, Unnasch TR, Garms R, Hudson-Davis L, et al. After 70 years of fighting an age-old scourge, onchocerciasis in Uganda, the end is in sight. Int Health. 2018;10(Suppl 1):i79–i88.CrossRefPubMed
19.
go back to reference Forrer A, Wanji S, Obie ED, Nji TM, Hamill L, Ozano K, et al. Why onchocerciasis transmission persists after 15 annual ivermectin mass drug administrations in South-West Cameroon. BMJ Glob Health. 2021;11:6e003248. Forrer A, Wanji S, Obie ED, Nji TM, Hamill L, Ozano K, et al. Why onchocerciasis transmission persists after 15 annual ivermectin mass drug administrations in South-West Cameroon. BMJ Glob Health. 2021;11:6e003248.
20.
go back to reference Brieger WR, Okeibunor JC, Abiose AO, Ndyomugyenyi R, Wanji S, Elhassan E, et al. Characteristics of persons who complied with and failed to comply with annual ivermectin treatment. Trop Med Int Health. 2012;17:920–30.CrossRefPubMed Brieger WR, Okeibunor JC, Abiose AO, Ndyomugyenyi R, Wanji S, Elhassan E, et al. Characteristics of persons who complied with and failed to comply with annual ivermectin treatment. Trop Med Int Health. 2012;17:920–30.CrossRefPubMed
21.
go back to reference Senyonjo L, Oye J, Bakajika D, Biholong B, Tekle A, Boakye D, et al. Factors associated with ivermectin non-compliance and its potential role in sustaining Onchocerca volvulus transmission in the West Region of Cameroon. PLoS Negl Trop Dis. 2016;10:e0004905.CrossRefPubMedPubMedCentral Senyonjo L, Oye J, Bakajika D, Biholong B, Tekle A, Boakye D, et al. Factors associated with ivermectin non-compliance and its potential role in sustaining Onchocerca volvulus transmission in the West Region of Cameroon. PLoS Negl Trop Dis. 2016;10:e0004905.CrossRefPubMedPubMedCentral
22.
go back to reference Shuford KV, Turner HC, Anderson RM. Compliance with anthelmintic treatment in the neglected Tropical Diseases control programmes: a systematic review. Parasit Vectors. 2016;9:29.CrossRefPubMedPubMedCentral Shuford KV, Turner HC, Anderson RM. Compliance with anthelmintic treatment in the neglected Tropical Diseases control programmes: a systematic review. Parasit Vectors. 2016;9:29.CrossRefPubMedPubMedCentral
23.
go back to reference Osei FA, Newton S, Nyanor I, Osei-Yeboah E, Amuzu EX, Mensah NK, et al. Mass drug administration targeting Onchocerca volvulus in Owabi catchment area in Ashanti Region, Ghana: determinants of drug coverage and drug uptake. Parasite Epidemiol Control. 2022;16:e00235.CrossRefPubMed Osei FA, Newton S, Nyanor I, Osei-Yeboah E, Amuzu EX, Mensah NK, et al. Mass drug administration targeting Onchocerca volvulus in Owabi catchment area in Ashanti Region, Ghana: determinants of drug coverage and drug uptake. Parasite Epidemiol Control. 2022;16:e00235.CrossRefPubMed
24.
go back to reference Kifle B, Nigatu M. Compliance to a five-year biannual ivermectin treatment for onchocerciasis elimination and its determinants among adults in the Bench Maji Zone, Southwest Ethiopia: a community-based cross-sectional study. J Parasitol Res. 2021;2021:8866639.CrossRefPubMedPubMedCentral Kifle B, Nigatu M. Compliance to a five-year biannual ivermectin treatment for onchocerciasis elimination and its determinants among adults in the Bench Maji Zone, Southwest Ethiopia: a community-based cross-sectional study. J Parasitol Res. 2021;2021:8866639.CrossRefPubMedPubMedCentral
25.
go back to reference Otabil KB, Basáñez MG, Opoku SA, Kyei DO et al. Persistence of onchocerciasis and associated dermatologic and ophthalmic pathologies after 27 years of ivermectin mass drug administration in the middle belt of Ghana. Trop Med Int Health. 2023 (under review). Otabil KB, Basáñez MG, Opoku SA, Kyei DO et al. Persistence of onchocerciasis and associated dermatologic and ophthalmic pathologies after 27 years of ivermectin mass drug administration in the middle belt of Ghana. Trop Med Int Health. 2023 (under review).
26.
27.
go back to reference O’Hanlon SJ, Slater HC, Cheke RA, Boatin BA, Coffeng LE, Pion SDS, et al. Model-based geostatistical mapping of the prevalence of Onchocerca volvulus in West Africa. PLoS Negl Trop Dis. 2016;10:e0004328.CrossRefPubMedPubMedCentral O’Hanlon SJ, Slater HC, Cheke RA, Boatin BA, Coffeng LE, Pion SDS, et al. Model-based geostatistical mapping of the prevalence of Onchocerca volvulus in West Africa. PLoS Negl Trop Dis. 2016;10:e0004328.CrossRefPubMedPubMedCentral
28.
go back to reference Stolk WA, Borsboom GJJM, Habbema JDF. Trends in Infection prevalence in the special intervention zones of the former OCP and future expectations: final report. Rotterdam, The Netherlands: Erasmus Medical Center; 2011. Stolk WA, Borsboom GJJM, Habbema JDF. Trends in Infection prevalence in the special intervention zones of the former OCP and future expectations: final report. Rotterdam, The Netherlands: Erasmus Medical Center; 2011.
32.
go back to reference Forson AO, Awuah RB, Mohammed AR, Owusu-Asenso CM, Atakora SB, Akosah-Brempong G, et al. Perceptions of the roles, impact, challenges and needs of community drug distributors in the control and elimination of neglected Tropical Diseases in difficult-to-access communities in Ghana. BMC Infect Dis. 2023;23:460.CrossRefPubMedPubMedCentral Forson AO, Awuah RB, Mohammed AR, Owusu-Asenso CM, Atakora SB, Akosah-Brempong G, et al. Perceptions of the roles, impact, challenges and needs of community drug distributors in the control and elimination of neglected Tropical Diseases in difficult-to-access communities in Ghana. BMC Infect Dis. 2023;23:460.CrossRefPubMedPubMedCentral
33.
go back to reference Weldegebreal F, Medhin G, Weldegebriel Z, Legesse M. Knowledge, attitude and practice of community drug distributors about onchocerciasis and community directed treatment with ivermectin in Quara district, North Western Ethiopia. BMC Res Notes. 2016;9:206.CrossRefPubMedPubMedCentral Weldegebreal F, Medhin G, Weldegebriel Z, Legesse M. Knowledge, attitude and practice of community drug distributors about onchocerciasis and community directed treatment with ivermectin in Quara district, North Western Ethiopia. BMC Res Notes. 2016;9:206.CrossRefPubMedPubMedCentral
34.
go back to reference Slovin E. Slovin’s formula for sampling technique, 1960. Cited in Guilford JP, Frucher B. Fundamental Statistics in Psychology and Education, New York: MC Graw-Hill. 1973. Slovin E. Slovin’s formula for sampling technique, 1960. Cited in Guilford JP, Frucher B. Fundamental Statistics in Psychology and Education, New York: MC Graw-Hill. 1973.
35.
go back to reference World Health Organization & African Programme for Onchocerciasis Control. Guidelines for revising ivermectin treatment boundaries within the context of onchocerciasis elimination. African Programme for Onchocerciasis Control. 2015. Available from: https://apps.who.int/iris/handle/10665/343029 [Accessed 10 September 2023]. World Health Organization & African Programme for Onchocerciasis Control. Guidelines for revising ivermectin treatment boundaries within the context of onchocerciasis elimination. African Programme for Onchocerciasis Control. 2015. Available from: https://​apps.​who.​int/​iris/​handle/​10665/​343029 [Accessed 10 September 2023].
36.
go back to reference Endale A, Erko B, Weldegebreal F, Legesse M. Predictors of compliance with community-directed treatment with ivermectin for onchocerciasis control in Kabo area, southwestern Ethiopia. Parasit Vectors. 2015;8:99.CrossRefPubMedPubMedCentral Endale A, Erko B, Weldegebreal F, Legesse M. Predictors of compliance with community-directed treatment with ivermectin for onchocerciasis control in Kabo area, southwestern Ethiopia. Parasit Vectors. 2015;8:99.CrossRefPubMedPubMedCentral
37.
go back to reference Nuwaha F, Okware J, Ndyomugyenyi R. Predictors of compliance with community-directed ivermectin treatment in Uganda: quantitative results. Trop Med Int Health. 2005;10:659–67.CrossRefPubMed Nuwaha F, Okware J, Ndyomugyenyi R. Predictors of compliance with community-directed ivermectin treatment in Uganda: quantitative results. Trop Med Int Health. 2005;10:659–67.CrossRefPubMed
38.
go back to reference Kamga GR, Dissak-Delon FN, Nana-Djeunga HC, Biholong BD, Ghogomu SM, Souopgu J, et al. Audit of the community-directed treatment with ivermectin (CDTI) for onchocerciasis and factors associated with adherence in three regions of Cameroon. Parasit Vectors. 2018;11:356.CrossRefPubMedPubMedCentral Kamga GR, Dissak-Delon FN, Nana-Djeunga HC, Biholong BD, Ghogomu SM, Souopgu J, et al. Audit of the community-directed treatment with ivermectin (CDTI) for onchocerciasis and factors associated with adherence in three regions of Cameroon. Parasit Vectors. 2018;11:356.CrossRefPubMedPubMedCentral
39.
go back to reference Agyemang ANO, Badu K, Baffour-Awuah S, Owusu-Dabo E, Biritwum NK, Garms R, et al. Evaluation of onchocerciasis control in the Upper Denkyira East municipal in the forest area of Ghana: responses of participants and distributors to the CDTI programme. Acta Trop. 2018;185:357–62.CrossRefPubMed Agyemang ANO, Badu K, Baffour-Awuah S, Owusu-Dabo E, Biritwum NK, Garms R, et al. Evaluation of onchocerciasis control in the Upper Denkyira East municipal in the forest area of Ghana: responses of participants and distributors to the CDTI programme. Acta Trop. 2018;185:357–62.CrossRefPubMed
40.
go back to reference Wanji S, Kengne-Ouafo JA, Esum ME, Chounna PW, Adzemye BF, Eyong JE, et al. Relationship between oral declaration on adherence to ivermectin treatment and parasitological indicators of onchocerciasis in an area of persistent transmission despite a decade of mass drug administration in Cameroon. Parasit Vectors. 2015;8:667.CrossRefPubMedPubMedCentral Wanji S, Kengne-Ouafo JA, Esum ME, Chounna PW, Adzemye BF, Eyong JE, et al. Relationship between oral declaration on adherence to ivermectin treatment and parasitological indicators of onchocerciasis in an area of persistent transmission despite a decade of mass drug administration in Cameroon. Parasit Vectors. 2015;8:667.CrossRefPubMedPubMedCentral
41.
go back to reference Makenga Bof JC, Muteba D, Mansiangi P, Ilunga-Ilunga F, Coppieters Y. Analysis of severe adverse effects following community-based ivermectin treatment in the Democratic Republic of Congo. BMC Pharmacol Toxicol. 2019;20:49.CrossRefPubMedPubMedCentral Makenga Bof JC, Muteba D, Mansiangi P, Ilunga-Ilunga F, Coppieters Y. Analysis of severe adverse effects following community-based ivermectin treatment in the Democratic Republic of Congo. BMC Pharmacol Toxicol. 2019;20:49.CrossRefPubMedPubMedCentral
42.
go back to reference Kifle B, Woldemichael Kifle, Nigatu M. Prevalence of onchocerciasis and associated factors among adults aged ≥ 15 years in Semen Bench District, Bench Maji Zone, Southwest Ethiopia: community based cross-sectional study. Adv Publ Health. 2019;2019:7276230.CrossRef Kifle B, Woldemichael Kifle, Nigatu M. Prevalence of onchocerciasis and associated factors among adults aged ≥ 15 years in Semen Bench District, Bench Maji Zone, Southwest Ethiopia: community based cross-sectional study. Adv Publ Health. 2019;2019:7276230.CrossRef
43.
go back to reference Hamilton P, O’Hanlon S, Milton P, Osei-Atweneboana M, Walker M, Basáñez MG. Patterns of population movement and ivermectin adherence in onchocerciasis foci in Ghana. Research in Progress Annual Meeting, Royal Society of Tropical Medicine and Hygiene, London, 5th December 2018 (poster presentation). Hamilton P, O’Hanlon S, Milton P, Osei-Atweneboana M, Walker M, Basáñez MG. Patterns of population movement and ivermectin adherence in onchocerciasis foci in Ghana. Research in Progress Annual Meeting, Royal Society of Tropical Medicine and Hygiene, London, 5th December 2018 (poster presentation).
44.
go back to reference Gil-Lacruz M, Gil-Lacruz AI. Health perception and health care access: sex differences in behaviors and attitudes. Am J Econ Sociol. 2010;69:783–801.CrossRef Gil-Lacruz M, Gil-Lacruz AI. Health perception and health care access: sex differences in behaviors and attitudes. Am J Econ Sociol. 2010;69:783–801.CrossRef
46.
go back to reference Nicolas P, Maia MF, Bassat Q, Kobylinski KC, Monteiro W, Rabinovich NR, et al. Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis. Lancet Glob Health. 2020;8:e92–e100.CrossRefPubMedPubMedCentral Nicolas P, Maia MF, Bassat Q, Kobylinski KC, Monteiro W, Rabinovich NR, et al. Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis. Lancet Glob Health. 2020;8:e92–e100.CrossRefPubMedPubMedCentral
47.
go back to reference Erber AC, Ariyo E, Olliaro P, Nicolas P, Chaccour C, Colebunders R. Treatment of pregnant women with ivermectin during mass Drug Distribution: time to investigate its safety and potential benefits. Pathogens. 2021;10:1588.CrossRefPubMedPubMedCentral Erber AC, Ariyo E, Olliaro P, Nicolas P, Chaccour C, Colebunders R. Treatment of pregnant women with ivermectin during mass Drug Distribution: time to investigate its safety and potential benefits. Pathogens. 2021;10:1588.CrossRefPubMedPubMedCentral
48.
go back to reference Homeida MM, Malcolm SB, ElTayeb AZ, Eversole RR, Elassad AS, Geary TG, et al. The lack of influence of food and local alcoholic brew on the blood level of Mectizan® (ivermectin). Acta Trop. 2013;127:97–100.CrossRefPubMed Homeida MM, Malcolm SB, ElTayeb AZ, Eversole RR, Elassad AS, Geary TG, et al. The lack of influence of food and local alcoholic brew on the blood level of Mectizan® (ivermectin). Acta Trop. 2013;127:97–100.CrossRefPubMed
49.
go back to reference Brieger WR, Okeibunor JC, Abiose AO, Wanji S, Elhassan E, Ndyomugyenyi R, et al. Compliance with eight years of annual ivermectin treatment of onchocerciasis in Cameroon and Nigeria. Parasit Vectors. 2011;4:152.CrossRefPubMedPubMedCentral Brieger WR, Okeibunor JC, Abiose AO, Wanji S, Elhassan E, Ndyomugyenyi R, et al. Compliance with eight years of annual ivermectin treatment of onchocerciasis in Cameroon and Nigeria. Parasit Vectors. 2011;4:152.CrossRefPubMedPubMedCentral
50.
go back to reference Dissak-Delon FN, Kamga GR, Humblet PC, Robert A, Souopgui J, Kamgno J, et al. Adherence to ivermectin is more associated with perceptions of community-directed treatment with ivermectin organization than with onchocerciasis beliefs. PLoS Negl Trop Dis. 2017;11(8):1–17.CrossRef Dissak-Delon FN, Kamga GR, Humblet PC, Robert A, Souopgui J, Kamgno J, et al. Adherence to ivermectin is more associated with perceptions of community-directed treatment with ivermectin organization than with onchocerciasis beliefs. PLoS Negl Trop Dis. 2017;11(8):1–17.CrossRef
Metadata
Title
Non-adherence to ivermectin in onchocerciasis-endemic communities with persistent infection in the Bono Region of Ghana: a mixed-methods study
Authors
Kenneth Bentum Otabil
María-Gloria Basáñez
Blessing Ankrah
Emmanuel John Bart-Plange
Theophilus Nti Babae
Prince-Charles Kudzordzi
Vera Achiaa Darko
Abdul Sakibu Raji
Lydia Datsa
Andrews Agyapong Boakye
Michael Tawiah Yeboah
Joseph Nelson Siewe Fodjo
Henk D. F. H. Schallig
Robert Colebunders
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2023
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-023-08806-8

Other articles of this Issue 1/2023

BMC Infectious Diseases 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine